Chemgenex Pharmaceut
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 22 July 2011
- Reported shorts
- 2.2K
- Shares on issue
- 313.559M
Chemgenex Pharmaceut (ASX:CXS) has no reportable short positions in the latest ASIC data as of 22 July 2011.
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Chemgenex Pharmaceuticals was an Australian biotechnology company focused on the development of small molecule therapeutics for cancer and other life-threatening diseases. Its primary asset was OMAPRO (omacetaxine mepesuccinate), a drug for chronic myeloid leukemia (CML). The company aimed to bring novel treatments through clinical trials to market, positioning itself in the niche area of hematological malignancies.
Company profile →Chemgenex Pharmaceut (ASX:CXS) has no reportable short positions as of 22 July 2011. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 2.18 percentage points. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 46, 2026.
Company information is being updated. Check back soon.
Be the first to discuss CXS
Start a research thread or post the first pulse update